RxDoctor Payments Data

Lisa Lownsbury, DO

Psychiatry · Scottsdale, AZNPI 1043616063

Payments from drug & device makers

$669in general payments, 2019–2025

Across 34 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$249
  • Teva Pharmaceuticals USA, Inc.$179
  • Alkermes, Inc.$103
  • Sunovion Pharmaceuticals Inc.$54
  • Indivior Inc.$25
  • Takeda Pharmaceuticals U.S.A., Inc.$17
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669 in reported general payments places this provider in the 65th percentile of 573 psychiatry providers in Arizona.

See all psychiatry providers in Arizona

Medicare billing

Part B allowed, 2024
$3,841
Medicare patients
17
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$183,385
Invega SustennaPaliperidone Palmitate36$101,571
AristadaAripiprazole Lauroxil26$70,544
Abilify MaintenaAripiprazole20$58,162
Risperdal ConstaRisperidone Microspheres11$14,325
Lurasidone Hcl39$7,027
Clozapine60$4,379
Quetiapine Fumarate119$3,507
Ziprasidone Hcl54$3,007
Divalproex Sodium ErDivalproex Sodium52$2,898
Aripiprazole82$2,738
Trazodone Hcl172$2,126
Fluphenazine Hcl13$1,480
Hydroxyzine Hcl41$1,382
Paliperidone ErPaliperidone14$1,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$179$184,20128 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$249$115,89747 claims
Alkermes, Inc.Aristada$103$70,54426 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$11$58,16220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 573 psychiatry providers in Arizona.

Other psychiatry in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →